# Australian Technical Advisory Group on Immunisation (ATAGI)

## Summary of the 103rd meeting, 14 March 2024

### Respiratory syncytial virus (RSV)

* ATAGI reviewed and discussed its draft statement on the clinical use of nirsevimab, a long-acting monoclonal antibody against RSV, as an immunisation strategy to prevent RSV in infants. This [statement](https://www.health.gov.au/resources/publications/atagi-statement-on-nirsevimab-2024) was published on 26 March 2024 on the Department of Health and Aged Care website.
* ATAGI reviewed and discussed the draft RSV chapter, which when finalised will be published in the [Australian Immunisation Handbook](https://immunisationhandbook.health.gov.au/).

### Departmental updates

* ATAGI received an update from the Therapeutic Goods Administration (TGA) on several vaccines that are currently under evaluation for registration in Australia.

### Other business

* ATAGI noted that Ms Catherine Radkowski is no longer on the Jurisdictional Immunisation Committee and a new representative will be appointed to ATAGI. Members thanked Ms Radkowski for her contributions to ATAGI.

### Resources

* ATAGI’s membership, terms of reference and declaration of interest information is available on the [Department of Health and Aged Care website](https://www.health.gov.au/committees-and-groups/australian-technical-advisory-group-on-immunisation-atagi?language=und).